Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA ...

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Pfizer, BioNTech and Moderna lose bids to dismiss Bayer patent lawsuits alleging their COVID-19 vaccines use Monsanto-developed mRNA technology.

A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. Moderna is ...

Pfizer Inc PFE shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after ...

Mon, May 4, 2026 at 2:09 PM UTC Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life after the pandemic ...

Washington: A federal judge in Delaware on Monday rejected Pfizer, BioNTech and Moderna's requests to dismiss patent lawsuits filed against them by Bayer's Monsanto unit over the messenger ...

A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests ​to dismiss patent lawsuits filed against them by Bayer's ‌Monsanto unit over the messenger RNA technology used ...